Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Mar;32(3):369–373. doi: 10.1128/aac.32.3.369

Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis.

R M Tucker 1, P L Williams 1, E G Arathoon 1, B E Levine 1, A I Hartstein 1, L H Hanson 1, D A Stevens 1
PMCID: PMC172178  PMID: 2835002

Abstract

The pharmacokinetics of fluconazole, a new oral azole, were evaluated in cerebrospinal fluid and sera of eight patients with coccidioidal meningitis. At a dose of 50 mg/day, peak concentrations of 2.5 to 3.5 and 2.0 to 2.3 micrograms/ml occurred at 2 to 6 and 4 to 8 h in serum and cerebrospinal fluid, respectively. At 100 mg/day, peak concentrations of 4.5 to 8.0 and 3.4 to 6.2 micrograms/ml occurred at 2 to 4 and 4 to 12 h, respectively. The mean ratios of the concentration in cerebrospinal fluid to that in serum were 73.8% at 50 mg/day and 88.7% at 100 mg/day. Results suggested that there was a prolonged half-life in both cerebrospinal fluid and serum and that it was slightly longer in the former. Minimal toxicity was noted in 34 patient months of therapy (12 months on 50 mg daily; 22 months on 100 mg daily). After a mean of 4.5 months of therapy, five patients responded to therapy and three were unevaluable. The penetration of fluconazole into cerebrospinal fluid was substantial, toxicity was minimal, and early clinical experience was encouraging. Fluconazole holds promise as the sole or adjunctive therapy for fungal meningitis.

Full text

PDF
369

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brass C., Galgiani J. N., Blaschke T. F., Defelice R., O'Reilly R. A., Stevens D. A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982 Jan;21(1):151–158. doi: 10.1128/aac.21.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Craven P. C., Graybill J. R., Jorgensen J. H., Dismukes W. E., Levine B. E. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med. 1983 Feb;98(2):160–167. doi: 10.7326/0003-4819-98-2-160. [DOI] [PubMed] [Google Scholar]
  3. Dupont B., Drouhet E. Cryptococcal meningitis and fluconazole. Ann Intern Med. 1987 May;106(5):778–778. doi: 10.7326/0003-4819-106-5-778_2. [DOI] [PubMed] [Google Scholar]
  4. Graybill J. R., Sun S. H., Ahrens J. Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol. 1986 Apr;24(2):113–119. doi: 10.1080/02681218680000171. [DOI] [PubMed] [Google Scholar]
  5. Grosso D. S., Boyden T. W., Pamenter R. W., Johnson D. G., Stevens D. A., Galgiani J. N. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother. 1983 Feb;23(2):207–212. doi: 10.1128/aac.23.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hoeprich P. D., Finn P. D. Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis. 1972 Oct;126(4):353–361. doi: 10.1093/infdis/126.4.353. [DOI] [PubMed] [Google Scholar]
  7. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Janssen P. A., Symoens J. E. Hepatic reactions during ketoconazole treatment. Am J Med. 1983 Jan 24;74(1B):80–85. doi: 10.1016/0002-9343(83)90519-3. [DOI] [PubMed] [Google Scholar]
  9. Palou de Fernandez E., Patino M. M., Graybill J. R., Tarbit M. H. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother. 1986 Aug;18(2):261–270. doi: 10.1093/jac/18.2.261. [DOI] [PubMed] [Google Scholar]
  10. Perfect J. R., Durack D. T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. doi: 10.1093/jac/16.1.81. [DOI] [PubMed] [Google Scholar]
  11. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra C., Stevens D. A. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. doi: 10.7326/0003-4819-97-3-370. [DOI] [PubMed] [Google Scholar]
  13. Stevens D. A. Miconazole in the treatment of coccidioidomycosis. Drugs. 1983 Oct;26(4):347–354. doi: 10.2165/00003495-198326040-00004. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES